Literature DB >> 28689145

Allosteric regulation of epigenetic modifying enzymes.

Beth E Zucconi1, Philip A Cole2.   

Abstract

Epigenetic enzymes including histone modifying enzymes are key regulators of gene expression in normal and disease processes. Many drug development strategies to target histone modifying enzymes have focused on ligands that bind to enzyme active sites, but allosteric pockets offer potentially attractive opportunities for therapeutic development. Recent biochemical studies have revealed roles for small molecule and peptide ligands binding outside of the active sites in modulating the catalytic activities of histone modifying enzymes. Here we highlight several examples of allosteric regulation of epigenetic enzymes and discuss the biological significance of these findings.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28689145      PMCID: PMC5675028          DOI: 10.1016/j.cbpa.2017.05.015

Source DB:  PubMed          Journal:  Curr Opin Chem Biol        ISSN: 1367-5931            Impact factor:   8.972


  74 in total

Review 1.  Small Molecule Inhibitors of Protein Arginine Methyltransferases.

Authors:  Hao Hu; Kun Qian; Meng-Chiao Ho; Y George Zheng
Journal:  Expert Opin Investig Drugs       Date:  2016-02-16       Impact factor: 6.206

2.  Structure of the p300 catalytic core and implications for chromatin targeting and HAT regulation.

Authors:  Manuela Delvecchio; Jonathan Gaucher; Carmen Aguilar-Gurrieri; Esther Ortega; Daniel Panne
Journal:  Nat Struct Mol Biol       Date:  2013-08-11       Impact factor: 15.369

Review 3.  Chromatin modifiers and remodellers: regulators of cellular differentiation.

Authors:  Taiping Chen; Sharon Y R Dent
Journal:  Nat Rev Genet       Date:  2013-12-24       Impact factor: 53.242

4.  Expressed protein ligation: a general method for protein engineering.

Authors:  T W Muir; D Sondhi; P A Cole
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

5.  The histone demethylase RBP2 Is overexpressed in gastric cancer and its inhibition triggers senescence of cancer cells.

Authors:  Jiping Zeng; Zheng Ge; Lixiang Wang; Qiao Li; Na Wang; Magnus Björkholm; Jihui Jia; Dawei Xu
Journal:  Gastroenterology       Date:  2009-10-20       Impact factor: 22.682

6.  Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases.

Authors:  John R Horton; Amanda Engstrom; Elizabeth L Zoeller; Xu Liu; John R Shanks; Xing Zhang; Margaret A Johns; Paula M Vertino; Haian Fu; Xiaodong Cheng
Journal:  J Biol Chem       Date:  2015-12-08       Impact factor: 5.157

Review 7.  Handpicking epigenetic marks with PHD fingers.

Authors:  Catherine A Musselman; Tatiana G Kutateladze
Journal:  Nucleic Acids Res       Date:  2011-08-03       Impact factor: 16.971

8.  Critical role of histone demethylase RBP2 in human gastric cancer angiogenesis.

Authors:  Lupeng Li; Lixiang Wang; Ping Song; Xue Geng; Xiuming Liang; Minran Zhou; Yangyang Wang; Chunyan Chen; Jihui Jia; Jiping Zeng
Journal:  Mol Cancer       Date:  2014-04-09       Impact factor: 27.401

9.  Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.

Authors:  Sarah Picaud; Oleg Fedorov; Angeliki Thanasopoulou; Katharina Leonards; Katherine Jones; Julia Meier; Heidi Olzscha; Octovia Monteiro; Sarah Martin; Martin Philpott; Anthony Tumber; Panagis Filippakopoulos; Clarence Yapp; Christopher Wells; Ka Hing Che; Andrew Bannister; Samuel Robson; Umesh Kumar; Nigel Parr; Kevin Lee; Dave Lugo; Philip Jeffrey; Simon Taylor; Matteo L Vecellio; Chas Bountra; Paul E Brennan; Alison O'Mahony; Sharlene Velichko; Susanne Müller; Duncan Hay; Danette L Daniels; Marjeta Urh; Nicholas B La Thangue; Tony Kouzarides; Rab Prinjha; Jürg Schwaller; Stefan Knapp
Journal:  Cancer Res       Date:  2015-11-09       Impact factor: 12.701

10.  CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses.

Authors:  Ariane Hammitzsch; Cynthia Tallant; Oleg Fedorov; Alison O'Mahony; Paul E Brennan; Duncan A Hay; Fernando O Martinez; M Hussein Al-Mossawi; Jelle de Wit; Matteo Vecellio; Christopher Wells; Paul Wordsworth; Susanne Müller; Stefan Knapp; Paul Bowness
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-10       Impact factor: 11.205

View more
  4 in total

1.  Combination Targeting of the Bromodomain and Acetyltransferase Active Site of p300/CBP.

Authors:  Beth E Zucconi; Jessica L Makofske; David J Meyers; Yousang Hwang; Mingxuan Wu; Mitzi I Kuroda; Philip A Cole
Journal:  Biochemistry       Date:  2019-04-11       Impact factor: 3.162

Review 2.  Allosteric regulation of histone lysine methyltransferases: from context-specific regulation to selective drugs.

Authors:  Chen Davidovich; Qi Zhang
Journal:  Biochem Soc Trans       Date:  2021-04-30       Impact factor: 5.407

Review 3.  Histone Methyltransferase DOT1L as a Promising Epigenetic Target for Treatment of Solid Tumors.

Authors:  Elena Alexandrova; Annamaria Salvati; Giovanni Pecoraro; Jessica Lamberti; Viola Melone; Assunta Sellitto; Francesca Rizzo; Giorgio Giurato; Roberta Tarallo; Giovanni Nassa; Alessandro Weisz
Journal:  Front Genet       Date:  2022-04-13       Impact factor: 4.772

4.  Discovery of a Highly Selective Cell-Active Inhibitor of the Histone Lysine Demethylases KDM2/7.

Authors:  Philip A Gerken; Jamie R Wolstenhulme; Anthony Tumber; Stephanie B Hatch; Yijia Zhang; Susanne Müller; Shane A Chandler; Barbara Mair; Fengling Li; Sebastian M B Nijman; Rebecca Konietzny; Tamas Szommer; Clarence Yapp; Oleg Fedorov; Justin L P Benesch; Masoud Vedadi; Benedikt M Kessler; Akane Kawamura; Paul E Brennan; Martin D Smith
Journal:  Angew Chem Int Ed Engl       Date:  2017-11-07       Impact factor: 15.336

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.